ASCO 2021 | MGTA-145 and plerixafor for HSC mobilization in myeloma
Surbhi Sidana, MD, Stanford University, Stanford, CA, shares an update on a Phase II study (NCT04552743) of MGTA-145, a CXCR2 agonist, plus plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous stem cell transplant (auto-SCT) in patients with multiple myeloma. The primary endpoint of the study is collection of 2×10^6 CD34+ cells/kg within two days of mobilization/apheresis. Dr Sidana discusses the findings of interim analysis of data on mobilization from fifteen patients. 100% of patients met the primary endpoint. The secondary endpoint of 4 and 6×10^6 CD34+ cells/kg in two or less days was met by 90% and 80% of patients respectively. Overall, MGTA-145 was found to be well-tolerated. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
